To provide the information your oncologist is not telling you or doesn't have the time to!
On December 27, 2024, the FDA announced a significant milestone in cancer treatment: the approval ofĀ nivolumab and hyaluronidase-nvhy (Opdivo Qvantig)Ā for subcutaneous injection. This new formulation is available for all adult solid tumor indications previously approved for intravenous (IV) nivolumab, including a wide range of cancers such as melanoma, renal cell carcinoma, non-small cell lung cancer, …
For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …
In the world of oncology, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of certain B-cell malignancies like lymphomas and leukemias. But a recent study inĀ The New England Journal of MedicineĀ has opened the door to an entirely new application: using CAR T-cell therapy to treat severe autoimmune diseases such as systemic lupus erythematosus …
Hope for Advanced Bladder Cancer Bladder cancer is often like an unwelcome party crasher, popping up when least expected and causing considerable distress. Yet, in the realm of oncology, we are constantly seeking new ways to send such unwelcome guests packing. Today, I am thrilled to share some exciting news about a promising new approach …
Immunotherapy has made significant strides in cancer treatment, butĀ microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Ā has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that theĀ individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …
Small-cell lung cancer (SCLC) is a notoriously aggressive form of lung cancer, making up about 15% of all lung cancer cases. While treatments have made strides in extensive-stage SCLC, limited-stage SCLC has seen few advancements in decadesāuntil now. A new clinical trial published in the New England Journal of Medicine has revealed promising results with the use …
Breast Cancer Treatment October is Breast Cancer Awareness Month, a time dedicated to spreading knowledge, supporting research, and empowering patients and healthcare providers alike. Throughout the month, we’ll explore various critical aspects of breast cancer care. In this post, we focus on the current role of targeted therapies in treatment and encourage both patients and …
October is Breast Cancer Awareness Month, a time dedicated to spreading knowledge, supporting research, and empowering patients and healthcare providers alike. Throughout the month, we’ll explore various critical aspects of breast cancer care. In this post, we focus on the current role of immunotherapy in treatment and encourage both patients and providers to consider clinical …